Healthcare Startup Receives FDA approved

Last month VisionQuest Biomedical received FDA approval for their new practice: discovering ailments through eye imaging. The company wanted to prevent blindness in diabetic patients. It wanted to empower healthcare spaces with new equipment and new processes that could detect the medical illness early in order to prevent vision loss. Blindness in patients with diabetes comes from high blood sugar levels, which can damage the retina, called from diabetic retinopathy. This can only be diagnosed with a comprehensive eye exam, but in order to prevent blindness, it must be caught early and treated immediately. This early diagnosis doesn’t happen often enough. 

VisionQuest Biomedical thought of how they could better diagnose this ailment in a way that couldn’t be missed. So, they incorporated artificial intelligence (AI) into their products. With their software, a technician can take a picture of your retina and AI will analyze the image and provide a diagnosis. It’s a quick and simple test with AI that can recognize multiple forms of retinopathy and other causes of blindness. 

Are you adapting artificial intelligence to optimize your process? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts